Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Oral Maxillofac Surg ; 46(12): 1533-1538, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28751184

ABSTRACT

While effects of maxillomandibular advancement (MMA) on respiratory parameters for patients with obstructive sleep apnea (OSA) are well described, effects on sleep architecture before and after MMA are not. A retrospective cohort analysis on sleep architecture was examined in 10 OSA patients who underwent MMA surgery between July 2013 and November 2014, and had prespecified complete polysomnography (PSG) datasets. Sleep stages were examined relative to a Western European population-based control group. All of the respiratory parameters improved significantly post MMA. Rapid eye movement (REM) latency decreased from 178.0±142.8 to 96.6±64.5min (P=0.035). %NREM (non-rapid eye movement)1 (P=0.045) and %WASO (wakefulness after sleep onset) (P=0.006) decreased, while %REM increased (P=0.002) after MMA. WASO decreased from 64.2±57min to 22.4±15.4min (P=0.017). Preoperatively, OSA subjects showed significantly lower sleep efficiency (P=0.016), sleep onset latency (P=0.015), and % REM (P<0.001) than the normative population dataset, while post MMA there was a significant decrease in %NREM1 sleep (P<0.001) and in %WASO (P<0.001). MMA results in a marked decrease in WASO and increase in REM, and to a lesser extent NREM sleep. Patients after MMA show values similar to population controls except for a lower WASO.


Subject(s)
Mandibular Advancement/methods , Sleep Apnea, Obstructive/physiopathology , Sleep Apnea, Obstructive/surgery , Adult , Cross-Sectional Studies , Electroencephalography , Humans , Male , Polysomnography , Retrospective Studies , Sleep Stages/physiology , Sleep, REM/physiology , Treatment Outcome
2.
Sleep Med ; 33: 13-18, 2017 05.
Article in English | MEDLINE | ID: mdl-28449892

ABSTRACT

OBJECTIVE/BACKGROUND: The objective of this study was to evaluate medical comorbidity patterns in patients with a narcolepsy diagnosis in the United States. PATIENTS/METHODS: This was a retrospective medical claims data analysis. Truven Health Analytics MarketScan® Research Databases were accessed to identify individuals ≥18 years of age with ≥1 diagnosis code for narcolepsy (International Classification of Diseases (ICD)-9, 347.0, 347.00, 347.01, 347.1, 347.10, or 347.11) continuously insured between 2006 and 2010, and controls without narcolepsy matched 5:1 on age, gender, region, and payer. Narcolepsy and control subjects were compared for frequency of comorbid conditions, identified by the appearance of >1 diagnosis code(s) mapped to a Clinical Classification System (CCS) level 1 category any time during the study period, and on specific subcategories, including recognized narcolepsy comorbidities of obstructive sleep apnea (OSA) and depression. RESULTS: The final study group included 9312 subjects with narcolepsy and 46,559 controls (each group: average age, 46.1 years; 59% female). As compared with controls, patients with narcolepsy showed a statistically significant excess prevalence in all the CCS multilevel categories, the only exceptions being conditions originating in the perinatal period and pregnancy/childbirth complications. The greatest excess prevalence in the narcolepsy cohort was seen for mental illness (31.1% excess prevalence; odds ratio (OR) 3.8, 95% confidence interval (CI) 3.6, 4.0), followed by diseases of the digestive system (21.4% excess prevalence; OR 2.7, 95% CI 2.5, 2.8) and nervous system/sense organs (excluding narcolepsy; 20.7% excess prevalence; OR 3.7, 95% CI 3.4, 3.9). CONCLUSIONS: In this claims analysis, a narcolepsy diagnosis was associated with a wide range of comorbid medical illness claims, at significantly higher rates than matched controls.


Subject(s)
Comorbidity/trends , Cost of Illness , Narcolepsy/complications , Narcolepsy/diagnosis , Adult , Databases, Factual , Depression/complications , Depression/epidemiology , Female , Humans , Insurance Claim Review , Male , Middle Aged , Narcolepsy/epidemiology , Polysomnography/methods , Prevalence , Retrospective Studies , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/epidemiology , Sleep Apnea, Obstructive/physiopathology , United States/epidemiology
3.
J Vet Cardiol ; 19(1): 35-43, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27919727

ABSTRACT

OBJECTIVES: To describe signalment, clinical characteristics, diagnostic, treatment, and outcome data in a large case series of cats with patent ductus arteriosus (PDA). ANIMALS: Fifty cats with confirmed PDA. METHODS: Retrospective review of medical records from five referral veterinary hospitals for cats with PDA between 2000 and 2015. Cats were included if a PDA was visualized echocardiographically, during surgery, or on post-mortem examination. RESULTS: Median age at presentation was 6 months (range: 36 days-9.7 years; n = 50), and sex distribution was approximately equal (27 male, 23 female). Most cats did not have clinical signs (70.2%; 33/47) at the time of presentation. Murmurs were classified as continuous (55%; 22/40) or systolic (45%; 18/40). Echocardiography confirmed left-to-right shunting in 33 cats (82.5%; 33/40) and right-to-left shunting in 7 (17.5%; 7/40). Concurrent cardiac anomalies were identified in 54.5% (18/33) and pulmonary hypertension in 45.7% (16/35). Closure was pursued in 68% (34/50), and complications associated with the procedure occurred in 14.7% (5/34) of cats, including one intraoperative mortality. Long-term follow up was available in 80% (40/50) of cats. CONCLUSIONS: Cats with PDA often do not display clinical signs and may not have the characteristic physical examination findings typical of PDA in dogs. An increased prevalence of concurrent cardiac anomalies and pulmonary hypertension were found relative to previous reports. Thoracic radiographs and echocardiogram may provide the most comprehensive information for making a diagnosis and treatment recommendations. PDA closure was associated with a favorable long-term outcome in cats included in this study.


Subject(s)
Cat Diseases/physiopathology , Ductus Arteriosus, Patent/veterinary , Animals , Cat Diseases/diagnostic imaging , Cat Diseases/therapy , Cats , Ductus Arteriosus, Patent/diagnostic imaging , Ductus Arteriosus, Patent/physiopathology , Ductus Arteriosus, Patent/therapy , Echocardiography/veterinary , Female , Hypertension, Pulmonary/veterinary , Male , Radiography, Thoracic/veterinary , Retrospective Studies , Survival Analysis , Vascular Fistula/veterinary
4.
J Laryngol Otol ; 129(10): 974-9, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26333720

ABSTRACT

OBJECTIVE: To identify and systematically evaluate user-friendly smartphone snoring apps. METHODS: The Apple iTunes app store was searched for snoring apps that allow recording and playback. Snoring apps were downloaded, evaluated and rated independently by four authors. Two patients underwent polysomnography, and the data were compared with simultaneous snoring app recordings, and one patient used the snoring app at home. RESULTS: Of 126 snoring apps, 13 met the inclusion and exclusion criteria. The most critical app feature was the ability to graphically display the snoring events. The Quit Snoring app received the highest overall rating. When this app's recordings were compared with in-laboratory polysomnography data, app snoring sensitivities ranged from 64 to 96 per cent, and snoring positive predictive values ranged from 93 to 96 per cent. A chronic snorer used the app nightly for one month and tracked medical interventions. Snoring decreased from 200 to 10 snores per hour, and bed partner snoring complaint scores decreased from 9 to 2 (on a 0-10 scale). CONCLUSION: Select smartphone apps are user-friendly for recording and playing back snoring sounds. Preliminary comparison of more than 1500 individual snores demonstrates the potential clinical utility of such apps; however, further validation testing is recommended.


Subject(s)
Mobile Applications , Smartphone , Snoring/diagnosis , Humans , Polysomnography , Sensitivity and Specificity
5.
Cancer Gene Ther ; 20(12): 683-9, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24287722

ABSTRACT

PDX1 (pancreatic and duodenal homeobox 1) is overexpressed in pancreatic cancer, and its reduction results in tumor regression. Bi-functional pbi-shRNA PDX1 nanoparticle (OFHIRNA-PDX1) utilizes the endogenous micro-RNA biogenesis pathway to effect cleavage- and non-cleavage-dependent degradation of PDX1 mRNA. We have shown that OFHIRNA-PDX1 reduces pancreatic tumor volume in xenograft models. Thus, we are now exploring biorelevant large animal safety of OFHIRNA-PDX1. Mini pigs were chosen as the biorelevant species based on the similarity of human and pig PDX1 target sequence. In the initial study, animals developed fever, lethargy, hyporexia and cutaneous hyperemia following administration of OFHIRNA-PDX1. Twenty-one days later, the same animals demonstrated less toxicity with a second OFHIRNA-PDX1 infusion in conjunction with a prophylactic regimen involving dexamethasone, diphenhydramine, Indocin and ranitidine. In a new group of animals, PDX1 protein (31 kDa) expression in the pancreas was significantly repressed at 48 and 72 h (85%, P=0.018 and 88%, P=0.013; respectively) following a single infusion of OFHIRNA-PDX1 but recovered to normal state within 7 days. In conclusion, a single intravenous infusion of OFHIRNA-PDX1 in conjunction with premedication in pigs was well tolerated and demonstrated significant PDX1 knockdown.


Subject(s)
Homeodomain Proteins/genetics , Nanoconjugates , RNA, Small Interfering/genetics , Trans-Activators/genetics , Animals , Base Pairing , Base Sequence , Blood Glucose , Body Temperature , Cell Line, Tumor , Female , Gene Expression , Gene Order , Homeodomain Proteins/chemistry , Homeodomain Proteins/metabolism , Humans , Insulin/blood , Mice , Nanoconjugates/administration & dosage , Nanoconjugates/adverse effects , Nanoconjugates/chemistry , Plasmids/chemistry , Plasmids/genetics , Protein Isoforms , RNA Interference , RNA, Small Interfering/chemistry , RNA, Small Interfering/metabolism , Swine , Trans-Activators/chemistry , Trans-Activators/metabolism
7.
Aerosp Am ; 27(8): 38-41, 46, 1989 Aug.
Article in English | MEDLINE | ID: mdl-11540489

ABSTRACT

NASA: This article describes the use of robots to perform work in space. In particular, telerobotics, which uses human operators to control the movement and operation of the robots, are explored. The relationship between the human operator and the robot is very complex but these systems are being used to explore planetary surfaces and will also be used in the construction of the space station. Research being conducted at NASA facilities is described, providing a picture of the future of space robotics.^ieng


Subject(s)
Man-Machine Systems , Robotics/instrumentation , Space Flight/instrumentation , Equipment Design , Humans , Mars , Neural Networks, Computer , Robotics/trends , Space Flight/trends , Spacecraft/instrumentation
SELECTION OF CITATIONS
SEARCH DETAIL
...